age-related macular degeneration Archives -

News/ R&D/ Views & Analysis/ Views and analysis

Hope in sight with Apellis’ pegcetacoplan OAKS/DERBY results for GA

Nicole Raleigh age-related macular degeneration, Apellis, blindness, geographic atrophy, intravitreal injection, OAKS study, ophthalmology, pharma 0 Comment

Last month, pharmaphorum spoke with Dr Charles C. Wykoff about the results from Apellis Pharmaceuticals’ OAKS study on

Hope in sight with Apellis’ pegcetacoplan OAKS/DERBY results for GA

https://pharmaphorum.com/views-and-analysis/hope-in-sight-with-apellis-pegcetacoplan-oaks-derby-results-for-ga/

News/ News/ News/ R&D/ Sales and Marketing

Eylea data gives Regeneron/Bayer a lift in ophthalmic diseases

Phil Taylor age-related macular degeneration, Bayer, diabetic macular oedema, Eylea, ophthalmology, Regeneron, Roche, Vabysmo 0 Comment

A higher dose of Regeneron and Bayer’s Eylea given every three or four months has shown efficacy in

Eylea data gives Regeneron/Bayer a lift in ophthalmic diseases

https://pharmaphorum.com/news/eylea-data-gives-regeneron-bayer-a-lift-in-ophthalmic-diseases/

Market Access/ News/ News

FDA clears Roche’s Susvimo implant for eye disease wet AMD

Phil Taylor age-related macular degeneration, Bayer, Beovu, Eylea, Lucentis, Novartis, ophthalmology, Regeneron, Roche, Susvimo, wet AMD 0 Comment

Roche’s Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration

FDA clears Roche’s Susvimo implant for eye disease wet AMD

https://pharmaphorum.com/news/fda-clears-roches-susvimo-implant-for-eye-disease-wet-amd/

Market Access/ News/ News

FDA OKs first biosimilar of Roche’s blockbuster AMD drug Lucentis

Phil Taylor age-related macular degeneration, Biogen, Byooviz, Lucentis, ophthalmology, regulatory approval, Roche, Samsung Bioepis 0 Comment

Samsung Bioepis and Biogen have claimed the first FDA approval for a biosimilar version of Roche and Novartis’

FDA OKs first biosimilar of Roche’s blockbuster AMD drug Lucentis

https://pharmaphorum.com/news/fda-oks-first-biosimilar-of-roches-blockbuster-amd-drug-lucentis/

Market Access/ News/ News

FDA starts review of Roche’s eye disease drug, setting up 2022 verdict

Phil Taylor age-related macular degeneration, Bayer, Beovu, diabetic macular oedema, diabetic retinopathy, Eylea, faricimab, Novartis, ophthalmology, Regeneron, Roche 0 Comment

The FDA has started a priority review of Roche’s bispecific antibody faricimab for two major causes of blindness,

FDA starts review of Roche’s eye disease drug, setting up 2022 verdict

https://pharmaphorum.com/news/fda-starts-review-of-roches-eye-disease-drug-setting-up-2022-verdict/

Market Access/ News/ News

Roche eyes October decision by FDA for wet AMD implant

Phil Taylor age-related macular degeneration, Beovu, Eylea, fda, Lucentis, Novartis, ophthalmology, Regeneron, Roche, wet AMD 0 Comment

The FDA has started a review of a new implant version of Roche’s ranibizumab therapy for wet age-related

Roche eyes October decision by FDA for wet AMD implant

https://pharmaphorum.com/news/roche-eyes-october-decision-by-fda-for-wet-amd-implant/

Market Access/ News/ News

Novartis’ blockbuster hope Beovu clears EMA advisory panel

Phil Taylor age-related macular degeneration, Bayer, Beovu, Eylea, Lucentis, Novartis 0 Comment

Novartis could launch its new age-related macular degeneration drug in Europe early next year after getting a green

Novartis’ blockbuster hope Beovu clears EMA advisory panel

https://pharmaphorum.com/news/novartis-blockbuster-hope-beovu-clears-ema-advisory-panel/

News/ News/ R&D

Iveric rockets on mid-stage trial of Zimura in dry AMD

Phil Taylor age-related macular degeneration, blindness, geographic atrophy, Iveric Bio, Zimura 0 Comment

Shares in US biotech Iveric Bio have shot up after the company said its lead drug Zimura had

Iveric rockets on mid-stage trial of Zimura in dry AMD

https://pharmaphorum.com/news/iveric-rockets-on-mid-stage-trial-of-zimura-in-dry-amd/

News/ News/ R&D

Novartis backs brolucizumab with new head-to-head Eylea trial

Phil Taylor age-related macular degeneration, Bayer, brolucizumab, Eylea, Lucentis, Novartis, Regeneron 0 Comment

Novartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s

Novartis backs brolucizumab with new head-to-head Eylea trial

https://pharmaphorum.com/news/novartis-backs-brolucizumab-with-new-head-to-head-eylea-trial/

Trending

age-related macular degeneration

Login